Synaptogenix (SNPX) News Today $3.04 +0.10 (+3.40%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024August 16, 2024 | investorplace.comSynaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord InjuryJuly 19, 2024 | markets.businessinsider.comSynaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryJuly 18, 2024 | prnewswire.comSynaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisJune 26, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024May 20, 2024 | investorplace.comSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryMay 7, 2024 | prnewswire.comSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | finanznachrichten.deSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | prnewswire.comSynaptogenix announces reverse stock split to regain Nasdaq complianceApril 5, 2024 | uk.investing.comTrading was temporarily halted for "SNPX" at 07:04 PM with a stated reason of "News pending."April 5, 2024 | marketbeat.comWhat's Going On With Synaptogenix (SNPX) Stock?April 4, 2024 | msn.comSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingApril 3, 2024 | finance.yahoo.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%February 22, 2024 | msn.comSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersDecember 19, 2023 | finance.yahoo.comSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sDecember 6, 2023 | finance.yahoo.comSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNovember 2, 2023 | finance.yahoo.comSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseSeptember 26, 2023 | finance.yahoo.comBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudySeptember 7, 2023 | finance.yahoo.comSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisJuly 19, 2023 | prnewswire.comShort Volatility Alert: Synaptogenix IncJuly 14, 2023 | benzinga.comSynaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%July 13, 2023 | benzinga.comSynaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at ConferenceJuly 13, 2023 | marketwatch.comSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceJuly 13, 2023 | finance.yahoo.comTrading was temporarily halted for "SNPX" at 10:07 AM with a stated reason of "LULD pause."July 13, 2023 | marketbeat.comSNPX - Synaptogenix, Inc.June 24, 2023 | finance.yahoo.comSynaptogenix Provides Corporate Update and Outlines Potential Business OpportunitiesMarch 7, 2023 | finance.yahoo.comSNPX.OFebruary 27, 2023 | reuters.comPeering Into Synaptogenix's Recent Short InterestDecember 20, 2022 | msn.comSynaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate failsDecember 16, 2022 | seekingalpha.comSynaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's DiseaseDecember 16, 2022 | finance.yahoo.comSynaptogenix: Bryostatin For Alzheimer's, As Binary As Can BeDecember 9, 2022 | seekingalpha.comSynaptogenix announces $15M private placement with existing investorsNovember 18, 2022 | seekingalpha.comSynaptogenix Announces $15 Million Private Placement with Existing InvestorsNovember 18, 2022 | finance.yahoo.comCompanies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In GrowthOctober 22, 2022 | ca.finance.yahoo.comSynaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022October 19, 2022 | finance.yahoo.comSynaptogenix Welcomes Lecanemab Phase 3 Trial ResultsSeptember 28, 2022 | finance.yahoo.comSYNAPTOGENIX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K) - Marketscreener.comAugust 17, 2022 | marketscreener.com2022-08-12 | NDAQ:SNPX | Press Release | Synaptogenix Inc. - StockhouseAugust 12, 2022 | stockhouse.comSynaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network - Yahoo FinanceAugust 12, 2022 | finance.yahoo.comSynaptogenix Announces Live Ap - GuruFocus.comAugust 12, 2022 | gurufocus.comSynaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.comAugust 6, 2022 | marketscreener.comSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data - Yahoo FinanceJuly 26, 2022 | finance.yahoo.comSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data - PR NewswireJuly 26, 2022 | prnewswire.comSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 DataJuly 26, 2022 | finance.yahoo.comRecap of Wednesday’s Biotech Catalysts - End of The Day Summary - Benzinga - BenzingaJuly 20, 2022 | benzinga.comSynaptogenix Advances Dosing Of First Patient In Dose Optimization Clinical Trial In Preparation For NIH- - BenzingaJuly 20, 2022 | benzinga.com Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious drone activity triggers massive 1,366% surge (Ad)If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%. 👉 Click here now to see how this signal works. SNPX Media Mentions By Week SNPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNPX News Sentiment▼0.000.59▲Average Medical News Sentiment SNPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNPX Articles This Week▼10▲SNPX Articles Average Week Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRx Pharmaceuticals News Cara Therapeutics News Acurx Pharmaceuticals News Marinus Pharmaceuticals News TherapeuticsMD News HCW Biologics News AIM ImmunoTech News Sol-Gel Technologies News Aspira Women's Health News ImmunoPrecise Antibodies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNPX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
